Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers propose that the EDAR V370A allele's positive selection in East Asian populations may be linked to stable aquatic resources from Late Pleistocene ecosystems in northern China, suggesting a "nutritional niche construction" framework where these resources offset the allele's metabolic costs.

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

This study found that combining data from different databases provided a more comprehensive estimate of serious adverse drug reactions in a French university hospital, highlighting the limitations of current ADR reporting methods.

This study found that Agaricus bisporus-derived β-Glucan particles showed potential as an anticancer, antimicrobial, and antioxidant agent, inducing apoptosis and disrupting mitochondrial membrane potential in cervical cancer HeLa cells.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.

This study found that specific residues in human steroid 5alpha-reductase types 1 and 2 influence substrate binding and resistance to the inhibitor Finasteride, with certain substitutions significantly affecting these interactions.

This review analyzed the use of 5-alpha reductase inhibitors (5ARIs) for treating various dermatological conditions such as androgenetic alopecia, acne, and hirsutism, emphasizing their efficacy and safety profile.

This study found that the small signaling peptide RALF22 plays a key role in root hair growth response to volatile compounds emitted by Penicillium aurantiogriseum through ethylene, auxin, and photosynthesis signaling in Arabidopsis.

This review discusses various compounds targeting the androgen receptor, including recent developments in heterobifunctional degraders for prostate cancer treatment, but reports no new clinical results.

This study found that antisense oligonucleotides successfully reduced androgen receptor expression in human keratinocytes and reconstituted human epidermis, suggesting potential for developing topical treatments.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

In this case report, complete hair regrowth was observed in a patient with autoimmune-related alopecia areata after treatment with a Janus kinase inhibitor, suggesting its potential effectiveness for both genetic and sporadic forms of the condition.

This study suggests that the DORN1 receptor may play a role in eATP-induced changes in stomatal aperture in Arabidopsis thaliana, but not in the eADP signaling pathway.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

This study evaluated Korean herbal compounds in silico and identified Biochanin A, Saponin Re, and Emodin as potential topical treatments for androgenetic alopecia, each with specific safety and efficacy considerations.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

In this study, the researchers identified a temperature-sensitive mutant in Arabidopsis thaliana, showing disrupted root hair formation and altered responses to plant hormone treatments at elevated temperatures.

This study found that RXR and RAR proteins were detectable in normal human skin, suggesting they may play a role in epidermal cell differentiation and hair and gland physiology.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

This study developed a consensus document to guide danazol discontinuation in hereditary angioedema patients, enhancing the standardization and safety of treatment protocols.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

This study reported that Cosmerna ARI significantly improved androgenetic alopecia in Europeans over a 6-month period compared to a placebo, according to a double-blind, randomized, placebo-controlled clinical trial.

After the FDA's 2011 warning about a potential prostate cancer risk with 5-alpha reductase inhibitors, this study observed a significant decrease in their prescriptions, notably a 49% drop among men with benign prostatic hyperplasia, while primary care providers reduced prescriptions by 60%.

This discussion reviews the molecular mechanisms of ADP-induced platelet activation and suggests the P2Y1 receptor as a promising target for developing new antithrombotic drugs, without reporting new research findings.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

This study observed an increase in hair thickness and reduced hair loss in patients with androgenetic alopecia after treatment with autologous cellular suspension using the Rigenera® system, though further research is needed.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.